TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33775198

Group type: EXPERIMENTAL
Intervention: treadmill training with bilateral anodal tDCS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: treadmill training with unilateral anodal tDCS
Number of subjects: 80

Group type: COMPARATOR
Intervention: treadmill training with sham tDCS
Number of subjects: 80

Group type: COMPARATOR
Intervention: treadmill training (no tDCS)
Number of subjects: 80
Study: 35073324

Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide (PBO) pre-exposure followed by permethrin exposure in CDC bottle bioassays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic dose bioassays using permethrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcriptomic analysis
Number of subjects: 0
Study: 32755086

Group type: EXPERIMENTAL
Intervention: Ambu Aura-i
Number of subjects: 57

Group type: COMPARATOR
Intervention: Ambu Aura Gain
Number of subjects: 57
Study: 35551341

Group type: EXPERIMENTAL
Intervention: RD43 rice (Glycemic Index [GI] = 78) containing 14.1 g of undigestible starch daily as a substitute for two meals per day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RD43 rice
Number of subjects: 34

Group type: COMPARATOR
Intervention: Taiken9 rice (GI = 98)
Number of subjects: 34
Study: 33127241

Group type: EXPERIMENTAL
Intervention: Lay counselor–delivered school intervention
Number of subjects: 5539

Group type: EXPERIMENTAL
Intervention: Nurturing school environment (mediated by school climate)
Number of subjects: 5539
Study: 36451178

Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers (CCT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-recipients (Control)
Number of subjects: 39
Study: 34115148

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (17 mmol/l) with 5 mU [m2 BSA]−1 min−1 insulin
Number of subjects: 0
Study: 33745739

Group type: EXPERIMENTAL
Intervention: Prolonged postoperative mechanical ventilation (PPMV) defined as cumulative postoperative mechanical ventilation exceeding 72 h
Number of subjects: 108392

Group type: EXPERIMENTAL
Intervention: Neonatal age
Number of subjects: 108392

Group type: EXPERIMENTAL
Intervention: Preoperative inotropic support
Number of subjects: 108392

Group type: EXPERIMENTAL
Intervention: Operative time longer than 150 min
Number of subjects: 108392

Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists classification >3
Number of subjects: 108392
Study: 34609548

Group type: EXPERIMENTAL
Intervention: Standardized oral care bundle
Number of subjects: 3260

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 3260
Study: 32492354

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34673744

Group type: EXPERIMENTAL
Intervention: i-gelTM
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA SupremeTM
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ambu AuraGainTM
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 90
Study: 34823545

Group type: EXPERIMENTAL
Intervention: EDNA training group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (GRASP training)
Number of subjects: 17
Study: 32534578

Group type: EXPERIMENTAL
Intervention: 50 mg ipragliflozin daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Continuation of background treatment (non-SGLT2i)
Number of subjects: 110
Study: 35988175

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium nanoparticles topically
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (conventional placebo)
Number of subjects: 80
Study: 33710588

Group type: EXPERIMENTAL
Intervention: Complex weight-reducing interventions (structured weight reduction programme and sleeve gastrectomy when indicated)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard post-ablation medical care
Number of subjects: 160
Study: 32191193

Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Arterial Cannulation (USGAC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional Arterial Cannulation (AC)
Number of subjects: 60
Study: 35406038

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 7
Study: 34856777

Group type: EXPERIMENTAL
Intervention: BATHE consultation model
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care model (SOAP)
Number of subjects: 104
Study: 35883392

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of microfragmented adipose tissue
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 40
Study: 35746825

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combined educational and technological intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study: 33181788

Group type: EXPERIMENTAL
Intervention: Infant nevirapine
Number of subjects: 2025

Group type: EXPERIMENTAL
Intervention: High HBV VL
Number of subjects: 2025

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2025
Study: 36378149

Group type: EXPERIMENTAL
Intervention: iRoot SP (bioceramic sealer)
Number of subjects: 76

Group type: COMPARATOR
Intervention: AH Plus (resin-based sealer)
Number of subjects: 76
Study: 33933894

Group type: EXPERIMENTAL
Intervention: 0.2 mg buprenorphine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 42
Study: 32800303

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavior treatment (CBT)
Number of subjects: 47
Study: 35190442

Group type: EXPERIMENTAL
Intervention: Maximal tolerated ACE-I/ARB and spironolactone with patiromer
Number of subjects: 140

Group type: COMPARATOR
Intervention: Maximal tolerated ACE-I/ARB and spironolactone without patiromer
Number of subjects: 140
Study: 34139356

Group type: EXPERIMENTAL
Intervention: Cohort multiple randomised controlled trial (cmRCT) design
Number of subjects: 0
Study: 32147072

Group type: EXPERIMENTAL
Intervention: 2.25 g ginsenoside Rg3-enriched KRG & AG co-administration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 80
Study: 33973154

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34645102

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency stimulation of the suprascapular nerve
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-articular corticosteroid injection
Number of subjects: 20
Study: 35593540

Group type: EXPERIMENTAL
Intervention: 6-hour group disclosure intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 38
Study: 33411130

Group type: EXPERIMENTAL
Intervention: Fractional microneedle radiofrequency (MRF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 1565-nm non-ablative fractional laser (NAFL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both NAFL and MRF
Number of subjects: 14
Study: 32646502

Group type: EXPERIMENTAL
Intervention: Standard outpatient treatment plus prednisone (60 mg/24 h for 3 days, 30 mg/24 h for 3 days, and 15 mg/24 h for 3 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard outpatient treatment only (paracetamol 1 g/8 h on demand + hydroxychloroquine 400 mg/12h first day, 200 mg/12 h for 4 days + azithromycin 500 mg/24h for 5 days)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Standard outpatient treatment plus prednisone
Number of subjects: 200
Study: 35927929

Group type: EXPERIMENTAL
Intervention: Baska mask
Number of subjects: 64

Group type: COMPARATOR
Intervention: Endotracheal intubation (ET)
Number of subjects: 64
Study: 34174104

Group type: EXPERIMENTAL
Intervention: Intervention group (PE teachers received training to support psychological needs)
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Control group (PE teachers received no training)
Number of subjects: 1168
Study: 32651046

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35166922

Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO 50 U/kg three times weekly until discharge
Number of subjects: 24

Group type: COMPARATOR
Intervention: RBC transfusion if hemoglobin ≤ 7 g/dL and/or hemodynamic instability
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline EPO levels
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline lactic dehydrogenase levels
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maximum lactic dehydrogenase levels
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Creatinine peak
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dialysis duration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 24
Study: 32673006

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (COPE)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Seeking Safety (non-exposure intervention)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 81
Study: 34052365

Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PPARγ gene expression
Number of subjects: 20
Study: 36086543

Group type: EXPERIMENTAL
Intervention: PsmPy package for propensity score matching
Number of subjects: 0

Group type: COMPARATOR
Intervention: MatchIt package for propensity score matching
Number of subjects: 0
Study: 33879566

Group type: EXPERIMENTAL
Intervention: Teaching intervention including mental practice exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no mental practice exercises)
Number of subjects: 24
Study: 35697601

Group type: EXPERIMENTAL
Intervention: Combined sport-specific cognitive tests and 35-minute cycling time trial
Number of subjects: 25

Group type: COMPARATOR
Intervention: 35-minute cycling time trial
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sport-specific cognitive tests
Number of subjects: 25
Study: 33337729

Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive approach using streptokinase
Number of subjects: 266

Group type: COMPARATOR
Intervention: Early PPCI (?3 hrs)
Number of subjects: 266
Study: 34866234

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (2.5 g/6 h for 96 hours)
Number of subjects: 80
Study: 32971388

Group type: EXPERIMENTAL
Intervention: Addiction warning
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Psychosis warning
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Any warning
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Driving warning
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No warning
Number of subjects: 1000
Study: 33323233

Group type: EXPERIMENTAL
Intervention: RELF method (three-lead detection system with an automatic algorithm)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: RELF method
Number of subjects: 64
Study: 36409356

Group type: EXPERIMENTAL
Intervention: Guided dual technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 24
Study: 36451142

Group type: EXPERIMENTAL
Intervention: ClearlyMe® (self-directed use)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: ClearlyMe® with guided SMS support (guided use)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Digital psychoeducation (attention-matched control)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: ClearlyMe® (self-directed use) and ClearlyMe® with guided SMS support
Number of subjects: 489
Study: 32369661

Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchanges (TPE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham-TPE
Number of subjects: 38
Study: 36894736

Group type: EXPERIMENTAL
Intervention: Stress condition (n = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-Stress condition (n = 24)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Women using oral contraceptives (n = 9 in Stress, n = 10 in No-Stress)
Number of subjects: 48
Study: 33660906

Group type: EXPERIMENTAL
Intervention: Integrative Cognitive‐Affective Therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cognitive‐behavioural therapy administered using guided self‐help
Number of subjects: 112
Study: 32989046

Group type: EXPERIMENTAL
Intervention: Supraglottic airway device for surfactant administration
Number of subjects: 350

Group type: COMPARATOR
Intervention: Surfactant administration via endotracheal tube
Number of subjects: 350

Group type: COMPARATOR
Intervention: Continued CPAP
Number of subjects: 350
Study: 34749699

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard oxygen therapy (SOT)
Number of subjects: 10
Study: 32397980

Group type: EXPERIMENTAL
Intervention: Myrrh (500 mg capsules, three times a day for 2 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (three times a day for 2 weeks)
Number of subjects: 80
Study: 35182247

Group type: EXPERIMENTAL
Intervention: Nivolumab (360 mg every 3 weeks) plus ipilimumab (1 mg/kg every 6 weeks) combined with chemotherapy (2 cycles, every 3 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab combined with chemotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 58
Study: 34328501

Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behavioral therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: In-person cognitive behavioral therapy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Stepped-care group (internet-delivered therapy followed by in-person for nonresponders)
Number of subjects: 152

Group type: COMPARATOR
Intervention: In-person cognitive behavioral therapy alone
Number of subjects: 152
Study: 35587212

Group type: EXPERIMENTAL
Intervention: Flow weaning
Number of subjects: 113

Group type: COMPARATOR
Intervention: Direct weaning
Number of subjects: 113
Study: 36210517

Group type: EXPERIMENTAL
Intervention: Emergency TAVI in shock group
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Emergency TAVI in no shock group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Elective TAVI group
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Critically ill groups (shock and no shock)
Number of subjects: 179
Study: 33308680

Group type: EXPERIMENTAL
Intervention: Randomized response technique (Christofides' model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method of moment
Number of subjects: 0
Study: 35090412

Group type: EXPERIMENTAL
Intervention: Human library intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Didactic teaching session
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 45
Study: 33538831

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 3569

Group type: COMPARATOR
Intervention: cNRT
Number of subjects: 3569
Study: 32921472

Group type: EXPERIMENTAL
Intervention: Step‐28 (8 L/d of milk from d 11 to 28 and then 4 L/d from d 29 to 63)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Step‐56 (8 L/d of milk from d 11 to 56 and 4 L/d from d 57 to 63)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (8 L/d of milk from d 11 to 63 and abruptly weaned)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 48
Study: 34634640

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 33396852

Group type: EXPERIMENTAL
Intervention: College‐based Lifestyle Modification Program (College‐based LMP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study: 33861140

Group type: EXPERIMENTAL
Intervention: Side-by-side evaluation of virtual non-contrast (VNC) and post-contrast images
Number of subjects: 83

Group type: COMPARATOR
Intervention: Virtual non-contrast (VNC) images
Number of subjects: 83

Group type: COMPARATOR
Intervention: Post-contrast images
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Side-by-side evaluation of VNC and post-contrast images
Number of subjects: 83
Study: 36154950

Group type: EXPERIMENTAL
Intervention: High power condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low power condition
Number of subjects: 0
Study: 33707110

Group type: EXPERIMENTAL
Intervention: kV CBCT image matching process by radiation therapists (RTTs) and radiation oncologists (ROs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: kV CBCT image matching process
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: User's experience in image matching
Number of subjects: 12
Study: 35675693

Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient-based radiomic nomogram
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Clinical stage
Number of subjects: 174
Study: 33272960

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 35610658

Group type: EXPERIMENTAL
Intervention: CBSST-Peer
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: SST-Peer
Number of subjects: 252

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 252
Study: 33821935

Group type: EXPERIMENTAL
Intervention: TransFORM Body Treatment (TFB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bland moisturizer
Number of subjects: 0
Study: 35654374

Group type: EXPERIMENTAL
Intervention: Pathogenic variants in BRCA1
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Pathogenic variants in BRCA2
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Pathogenic variants in PALB2
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Pathogenic variants in moderate-risk genes (ATM, BARD1, CHEK2, RAD51C, RAD52D)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Lifetime risk for BRCA1 mutation carriers
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Lifetime risk for BRCA2 mutation carriers
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Lifetime risk for PALB2 mutation carriers
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Lifetime risk for moderate-risk gene carriers
Number of subjects: 871
Study: 34479631

Group type: EXPERIMENTAL
Intervention: Continued treatment
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Reduced or interrupted treatment
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Stopped treatment completely
Number of subjects: 278

Group type: COMPARATOR
Intervention: Discontinuation of treatment
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Reasons for stopping treatment
Number of subjects: 278
Study: 32453368

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication reduction (removal of 1 drug), n=282
Number of subjects: 569

Group type: COMPARATOR
Intervention: Usual care (no medication changes), n=287
Number of subjects: 569
Study: 36158122

Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 66
Study: 33638926

Group type: EXPERIMENTAL
Intervention: 0.15% ITR plus HA
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.15% ITR
Number of subjects: 92
Study: 32690011

Group type: EXPERIMENTAL
Intervention: Algorithm 1 (Dutch tariff)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm 2 (Dutch tariff)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm 3 (Dutch tariff)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observed utility (Dutch tariff)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observed utility (U.K. tariff)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing algorithms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preferred newly developed algorithm
Number of subjects: 0
Study: 33060043

Group type: EXPERIMENTAL
Intervention: HXT+VitE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 0
Study: 33126873

Group type: EXPERIMENTAL
Intervention: Balancing Everyday Life (BEL)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard Occupational Therapy (SOT)
Number of subjects: 226
Study: 36049477

Group type: EXPERIMENTAL
Intervention: Raltegravir-based cART
Number of subjects: 281

Group type: COMPARATOR
Intervention: Efavirenz-based cART
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Low weight gain group
Number of subjects: 281
Study: 35369315

Group type: EXPERIMENTAL
Intervention: Ankura II stent graft
Number of subjects: 132

Group type: COMPARATOR
Intervention: Ankura stent graft
Number of subjects: 132
Study: 32127890

Group type: EXPERIMENTAL
Intervention: Target controlled infusion (TCI) of propofol with an initial target effect‐site concentration of 4mcg/ml, followed by maintenance at 2.5mcg/ml, titrated by 0.5mcg/ml as needed.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intermittent bolus of propofol, starting with an initial bolus of 1mg/kg and repeat boluses of 0.25mg/kg.
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Target controlled infusion (TCI) of propofol.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intermittent bolus of propofol.
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both TCI and intermittent bolus of propofol.
Number of subjects: 176
Study: 34508557

Group type: EXPERIMENTAL
Intervention: High-dose SM03 (3600 mg, 600 mg × 6 infusions at weeks 0, 2, 4, 12, 14, and 16)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Low-dose SM03 (2400 mg, 600 mg × 4 infusions at weeks 0, 2, 12, and 14)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: High-dose SM03
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Low-dose SM03
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: SM03 (both doses)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: SM03
Number of subjects: 156
Study: 36470677

Group type: EXPERIMENTAL
Intervention: Fostamatinib (100-150 mg twice a day for 24 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 34